Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease
DED is a complex, multifactorial condition driven by a deficiency in natural tears, whether due to decreased tear production or increased tear evaporation. 5-7 Many commonly used DED treatment options have limitations, including slow onset, patient dissatisfaction and poor adherence. 8-14 Among surveyed dry eye patients, only 13% felt their dry eye was well managed. 14*
'Today marks a tremendous milestone for Alcon as TRYPTYR becomes our first prescription pharmaceutical treatment to be approved by the FDA since becoming an independent, publicly traded eye care company,' said David Endicott, CEO of Alcon. 'We look forward to making this new treatment available to millions of patients affected by Dry Eye Disease. We believe TRYPTYR is an exciting new treatment option for a significant number of dry eye patients given its rapid efficacy.'
This approval is supported by two Phase 3 clinical trials evaluating more than 930 patients (randomized 1:1 to TRYPTYR or vehicle) with a history of DED. 1-2 In COMET-2 and COMET-3, up to four times more TRYPTYR patients experienced at least a 10mm increase in natural tear production at Day 14, compared to vehicle, 42.6% versus 8.2% of patients in COMET-2 and 53.2% versus 14.4% in COMET-3 (both p<0.0001). 1-2 Consistent results were observed at all timepoints through Day 90. TRYPTYR demonstrated statistically significant natural tear production as early as Day 1. 1-2
'Many of my patients continue to face frustrating challenges with dry eye management, and there is a clear need for additional treatment options,' said Marjan Farid, MD, Professor of Ophthalmology at the University of California, Irvine. 'TRYPTYR is the first eye drop that stimulates corneal nerves to directly address tear deficiency, a known cause of Dry Eye Disease.'
Studies in animals suggest that acoltremon, the active substance in TRYPTYR, is an agonist of transient receptor potential melastatin 8 (TRPM8) thermoreceptors. TRPM8 thermoreceptor stimulation has been shown to activate trigeminal nerve signaling leading to increased basal tear production. The exact mechanism of action for TRYPTYR in DED is unknown.
TRYPTYR is available in easy-to-use, single dose vials: one drop per eye, two times a day. 3 Alcon expects to launch TRYPTYR in the U.S. in the third quarter of 2025 and anticipates bringing TRYPTYR to other markets in the future.
INDICATIONS AND USAGE
TRYPTYR (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.
Adverse Reactions
In clinical trials, the most common adverse reaction was instillation site pain (50%).
Please click here for the TRYPTYR Full Prescribing Information.
Forward-looking Statements
This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: 'anticipate,' 'intend,' 'commitment,' 'look forward,' 'maintain,' 'plan,' 'goal,' 'seek,' 'target,' 'assume,' 'believe,' 'project,' 'estimate,' 'expect,' 'strategy,' 'future,' 'likely,' 'may,' 'should,' 'will' and similar references to future periods.
Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties and risks that are difficult to predict. Some of these factors are discussed in our filings with the United States Securities and Exchange Commission, including our Form 20-F. Should one or more of these uncertainties or risks materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated. Therefore, you should not rely on any of these forward-looking statements.
Forward-looking statements in this press release speak only as of the date they are made, and we assume no obligation to update forward-looking statements as a result of new information, future events or otherwise.
About Dry Eye
Dry Eye Disease (DED) is one of the most common ocular surface disorders, affecting an estimated 38 million adults in the U.S. and an estimated 719 million more adults globally. 4 While once considered a disease of aging populations, modern advancements, such as prolonged digital screen time, have contributed to a significant rise in DED across age and gender. 15 Many existing prescription options for DED are generally regarded by many Eye Care Professionals and patients as inadequate due to low treatment efficacy, slow onset of action and/or poor tolerability. 16
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people's lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
References
*Based on an online survey conducted by Chronic Dry Eye from February to April 2021 among 415 responders who reported being diagnosed with chronic dry eye. 44% reported a severe level of chronic dry eye (i.e., levels 3 and 4).
Data on File for COMET-2 Phase 3 Study. Alcon 2025.
Data on File for COMET-3 Phase 3 Study. Alcon 2025.
TRYPTYR ® U.S. FDA Prescribing Information. 2025.
2023 Dry Eye Products Markets Report, Market Scope, 2023.
Craig JP, Nichols KK, Akpek EK, et al. TFOS DEWS II Definition and Classification Report. Ocul Surf. 2017;15(3):276-283. doi: 10.1016/j.jtos.2017.05.008.
Nattinen J, Aapola U, Nukareddy P, Uusitalo H. Looking deeper into ocular surface health: an introduction to clinical tear proteomics analysis. Acta Ophthalmol. 2022;100:486-498. doi: 10.1111/aos.15059.
Bron AJ, de Paiva CS, Chauhan SK, et al. TFOS DEWS II pathophysiology report. Ocul Surf. 2017;15:438-510. doi: 10.1016/j.jtos.2017.05.011.
Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114(1):76-79. doi: 10.1016/j.ophtha.2006.05.077.
Semba CP, Gadek TR. Development of lifitegrast: a novel T-cell inhibitor for the treatment of dry eye disease. Clin Ophthalmol. 2016;10:1083-1094. doi: 10.2147/OPTH.S110557.
Restasis. Prescribing Information. Allergan; 2012. Accessed July 8, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf.
Hovanesian JA, Nichols KK, Jackson M, et al. Real-world experience with lifitegrast ophthalmic solution (Xiidra ®) in the U.S. and Canada: retrospective study of patient characteristics, treatment patterns, and clinical effectiveness in 600 patients with dry eye disease. Clin Ophthalmol. 2021;15:1041-1054. doi: 10.2147/OPTH.S296510.
Cook N, Mullins A, Gautam R, et al. Evaluating patient experiences in dry eye disease through social media listening research. Ophthalmol Ther. 2019;8(3):407-420. doi: 10.1007/s40123-019-0188.
Mbagwu M, LaPrise A, Harris J, Nair AA, Fain J, Harrison DJ. Characterization of discontinuation and switching patterns of dry eye disease medications using linked EHR registry and claims data. Presented at: American Society for Cataract and Refractive Surgery Conference; April 5-6, 2024; Boston, MA.
Morse H, Henneberger S, Reed J, et al. 2021 in American survey findings: living with chronic dry eye. ChronicDryEye. August 10, 2021. Accessed September 23, 2024. https://chronicdryeye.net/infographic/in-america-findings.
The Relationship Between Dry Eye Disease and Digital Screen Use - PMC (nih.gov).
Improved Dry Eye Drugs for 2022 and Beyond; https://www.aao.org/eye-health/tips-prevention/new-dry-eye-treatments-ocular-surface-disease.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
an hour ago
- Los Angeles Times
LA Times Today: FDA panel on the use of antidepressants during pregnancy is alarming experts
Data shows as many as 20 percent of women experience depression during pregnancy. And in the first year after giving birth, suicide is a leading cause of death for an FDA panel recently attacked SSRI's – a class of antidepressant drugs – and their use during pregnancy. Some doctors say the panel is spreading misinformation about the drugs. L.A. Times science and medicine reporter Corinne Purtill joined Lisa McRee to explain.
The Hill
an hour ago
- The Hill
HHS will allow emergency use of animal drugs in New World screwworm fight
The Food and Drug Administration (FDA) became authorized on Tuesday to allow the use of animal drugs to treat or prevent infestations caused by the New World screwworm, a flesh-eating parasite that has recently disrupted the cattle industry. A declaration from the Department of Health and Human Services (HHS) will allow the FDA to issue emergency use authorizations for animal drugs to treat the insect. A spokesperson for HHS did not specify what medicines have been green-lit to combat the parasite. 'Our priority is to safeguard both animal health and the nation's food supply,' said FDA Commissioner Marty Makary. ' FDA is acting swiftly and responsibly to help ensure we have the necessary tools to prevent and control New World Screwworm, minimizing risks to agriculture and public health.' New World screwworms are a type of fly that lay their eggs in warm-blooded animals like cattle, horses, deer and even household pets like cats and dogs, according to the Department of Agriculture (USDA). Once the eggs hatch, the larvae can cause deadly damage to animals as they burrow into open wounds to feed on living tissue. In rare cases, the bugs have been known to attack humans, but HHS said in a statement that the current risk to human health in the U.S. 'remains very low.' But the potential future threat to animals and the country's food supply chain requires proactive action. USDA announced in May it would suspend all cattle, horse, and bison imports from Mexico after the bug was detected about 700 miles from the U.S. border in animals in Oaxaca and Veracruz. There are no FDA-approved drugs to treat the parasite in the U.S., but the agency can authorize the 'flexible, faster use' of certain animal drug products approved for other purposes or available in other countries under an emergency use authorization, according to a statement from HHS. 'Stopping this pest is a national security priority and we are linking arms across President Trump's cabinet to defend our borders and push back this threat,' said Agriculture Secretary Brooke L. Rollins.
Newsweek
an hour ago
- Newsweek
Shrimp Sold at Walmart May Be Radioactive: Warning Issued to Customers
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The Food and Drug Administration (FDA) warned Americans that some shrimp products sold at Walmart may contain a radioactive substance known as Cesium-137. Newsweek reached out to Walmart for comment via email. Why It Matters The FDA warned that repeated low-dose exposure to Cesium-137 includes an "elevated risk of cancer" caused by DNA damage. "Internal exposure to Cs-137, through ingestion or inhalation, allows the radioactive material to be distributed in the soft tissues, especially muscle tissue, exposing these tissues to the beta particles and gamma radiation and increasing cancer risk," reads a fact sheet on the substance from the Centers for Disease Control and Prevention (CDC). What To Know The warning applies to "certain raw frozen shrimp products processed by PT. Bahari Makmur Sejati (doing business as BMS Foods), a company located in Indonesia, and sold at Walmart," the FDA said in a press release. Cesium-137 was discovered in shipping containers found at ports in Los Angeles, Houston, Miami and Savannah, Georgia, according to the press release. The FDA collected samples for analysis, which confirmed the presence of the substance in one sample of the shrimp product. All containers and products testing positive or alerting for Cesium-137 have been denied entry into the country, and no product that has tested positive for it has entered U.S. commerce. Still, consumers are urged to throw away any of the impacted lots of Great Value shrimp products, the FDA said. Distributors and retailers were also urged to dispose of the product. Anyone who suspects they may have been exposed should talk to their health care provider, the press release said. The level of Cesium-137 detected in the products would not be enough to "pose an acute hazard to consumers," but smaller, consistent exposure could increase the risk of cancer, the FDA said. The following products are affected by the warning. Great Value brand frozen raw shrimp with a lot code of 8005540-1 and a best by date of March 15, 2027 Great Value brand frozen raw shrimp with a lot code of 8005538 and a best by date of March 15, 2027 Great Value brand frozen raw shrimp with a lot code of 8005539-1 and a best by date of March 15, 2027 Stock photo of a shrimp platter displayed with sauce on a plate. Stock photo of a shrimp platter displayed with sauce on a plate. anyaivanova/iStock via Getty Images What People Are Saying The FDA wrote: "Although testing to date has not confirmed the presence of contamination in any product in commerce, the product appears to have been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with Cs-137 and may pose a safety concern. To date, FDA has learned that Walmart has received implicated raw frozen shrimp, imported after the date of first detection of Cs-137 by CBP, but from shipments that did not alert for Cs-137. FDA has recommended Walmart recall this product." The CDC, on Cs-137: "People are exposed to some Cs-137 every day, because amounts of Cs-137 are present in the environment from weapons testing in the 1950s and 1960s. However, Cs-137 is dangerous in the large, concentrated amounts found in radiation therapy units and industrial gauges. The sources in these devices are designed to remain sealed and keep people from being exposed. If these canisters are intentionally or accidentally opened, the Cs-137 inside could be dispersed." What Happens Next The FDA said it "will continue working with industry to trace all implicated products processed by PT. Bahari Makmur Sejati through the supply chain to gather as much information about them as possible and take action as appropriate." The advisory will be updated as more information becomes available, the FDA said.
